Next Article in Journal
Medial Collateral Ligament Deficiency of the Elbow Joint: A Computational Approach
Next Article in Special Issue
Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis
Previous Article in Journal
Milieu for Endothelial Differentiation of Human Adipose-Derived Stem Cells
Article

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

1
Department of Biomedical Engineering and Biotechnology, University of Massachusetts, Lowell, MA 01854, USA
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3
Biomolecular Characterization Lab, Core Research Facility, University of Massachusetts Lowell, Lowell, MA 01854, USA
4
Department of Chemical Engineering, University of Massachusetts, Lowell, MA 01854, USA
*
Author to whom correspondence should be addressed.
Bioengineering 2018, 5(4), 83; https://doi.org/10.3390/bioengineering5040083
Received: 17 August 2018 / Revised: 4 October 2018 / Accepted: 6 October 2018 / Published: 9 October 2018
(This article belongs to the Collection Nanoparticles for Therapeutic and Diagnostic Applications)
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications. View Full-Text
Keywords: GSK461364A; Glioblastoma Multiforme; polymeric nanoparticles; cytotoxicity; enhanced permeability and retention; polo-like kinase inhibitor; oncology; oncomedicine; U-87 MG GSK461364A; Glioblastoma Multiforme; polymeric nanoparticles; cytotoxicity; enhanced permeability and retention; polo-like kinase inhibitor; oncology; oncomedicine; U-87 MG
Show Figures

Figure 1

MDPI and ACS Style

Velpurisiva, P.; Piel, B.P.; Lepine, J.; Rai, P. GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM). Bioengineering 2018, 5, 83. https://doi.org/10.3390/bioengineering5040083

AMA Style

Velpurisiva P, Piel BP, Lepine J, Rai P. GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM). Bioengineering. 2018; 5(4):83. https://doi.org/10.3390/bioengineering5040083

Chicago/Turabian Style

Velpurisiva, Praveena, Brandon P. Piel, Jack Lepine, and Prakash Rai. 2018. "GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)" Bioengineering 5, no. 4: 83. https://doi.org/10.3390/bioengineering5040083

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop